Vestipitant
Overview[edit]
Vestipitant is a selective neurokinin-1 receptor (NK1R) antagonist that has been investigated for its potential therapeutic effects in treating various conditions such as nausea, vomiting, and anxiety disorders. It is a member of the class of drugs known as substance P antagonists, which work by blocking the action of substance P, a neuropeptide involved in the transmission of pain and other sensory signals.
Chemical Structure[edit]
Vestipitant has a complex chemical structure that allows it to selectively bind to the NK1 receptor, inhibiting its activity. The molecular formula of Vestipitant is C23H21F6N3O, and it is characterized by the presence of multiple fluorine atoms, which contribute to its high affinity for the receptor.
Mechanism of Action[edit]
Vestipitant functions by competitively inhibiting the binding of substance P to the NK1 receptor. This receptor is predominantly found in the central nervous system and is involved in the regulation of emesis, pain, and stress response. By blocking this receptor, Vestipitant can reduce the symptoms associated with excessive activation of the NK1 pathway.
Clinical Applications[edit]
Vestipitant has been studied for its potential use in treating:
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
- Anxiety disorders
Although promising in preclinical studies, the clinical development of Vestipitant has faced challenges, and it is not currently approved for use in any major market.
Pharmacokinetics[edit]
Vestipitant is administered orally and is absorbed into the bloodstream, where it reaches peak plasma concentrations within a few hours. It is metabolized primarily in the liver and excreted through the urinary system. The drug has a half-life that allows for once-daily dosing in clinical settings.
Safety and Tolerability[edit]
In clinical trials, Vestipitant has been generally well-tolerated, with a safety profile similar to other NK1 receptor antagonists. Common side effects include mild headache, dizziness, and fatigue.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
